Cefodizine sodium (sterile) Pharma Grade API, also listed as cefodizime sodium under the WHO International Nonproprietary Name system, is a semisynthetic third-generation cephalosporin supplied as an off-white to pale-yellow hygroscopic powder. The product is assigned separate model designations for oral-grade and sterile injectable-grade material. The oral grade, commonly identified on batch records as cefodizine sodium oral/tablet/capsule/granule grade, is released with bioburden and solid-dosage physical specifications. The sterile injectable grade, identified as cefodizine sodium sterile EP-grade or equivalent, is released with parenteral-grade sterility, bacterial endotoxin, and particulate matter controls. The chemical identity is common to both designations: the active substance is the disodium salt of a semisynthetic cephalosporin, and the CAS registry number is 86329-79-5. The material is an active pharmaceutical ingredient, not a finished dosage form, and must undergo further pharmaceutical processing, filling, and final validated manufacturing at the dosage-form site.

The molecular formula is C20H18N6Na2O7S4 and the relative molecular mass is 628.6 g/mol. The powder is freely soluble in water, slightly soluble in ethanol, and practically insoluble in ethyl acetate; these solubility properties govern the choice of granulating fluids and the reconstitution medium for injection. The sterile designation is not created by gamma irradiation of the finished dry powder; beta-lactam cephalosporins are sensitive to radiation-induced free-radical degradation, and cefodizine sodium is therefore isolated by aseptic filtration of the crystallisation solution, followed by aseptic drying and packaging. Sterile-grade production typically includes membrane filtration through a 0.22 µm filter, drying at product temperature below 35°C, and discharge into sterile polyethylene/aluminium laminate containers under an ISO 14644-1 Class 5 environment. Oral-grade material may be isolated by conventional centrifuge and vacuum drying, but residual solvent removal still follows ICH Q3C and the relevant pharmacopoeial monograph. The distinction is operational, not chemical: the same synthesis route is used, but the final isolation train and environmental controls differ.

How Is the Sterile Injectable Grade Differentiated from Oral-Grade Cefodizine Sodium?

The injectable-grade material is controlled for five characteristics that the oral grade does not share at the same stringency: bacterial endotoxin, sterility, visible and subvisible particles, moisture content, and dissolved solution clarity. A typical sterile-grade lot is released with bacterial endotoxin not more than 0.10 EU/mg by Ph. Eur. 2.6.14 and is tested for sterility by membrane filtration according to Ph. Eur. 2.6.1. The oral-grade material is released against a bioburden specification, commonly not more than 100 CFU/g, with absence of Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, and Salmonella species per 1 g. Injectable-grade powder is packed in sterile double polyethylene bags inside aluminium drums, while oral-grade powder may be packed in non-sterile liners. The sterile grade is also controlled for particulate matter after reconstitution in water for injection; the relevant pharmacopoeial test is Ph. Eur. 2.9.19 for subvisible particles, with the liquid clarity visually assessed after dissolution. Failure to meet the clarity or particulate limit rejects the batch for parenteral use but does not automatically reject the same lot for oral solid-dosage use because the oral route does not require the same sterility assurance level.

For tablet and capsule manufacture, particle size distribution and powder flow are specification levers that are not defined by the pharmacopoeial monograph in most jurisdictions but are agreed between the API manufacturer and the dosage-form manufacturer. A representative oral-grade lot may be specified with D90 not more than 120 µm and D50 between 50 µm and 80 µm after pin milling, with bulk density of 0.30–0.65 g/mL and tapped density of 0.55–0.85 g/mL. The injectable-grade material is often controlled to a finer D90 of not more than 60 µm to permit reconstitution within 2 min for a 1 g dose in 10 mL of water for injection at 25°C. Powder flow indices such as Hausner ratio of 1.20–1.40 and Carr index of 20–35% are common release or internal limits for tableting grades because poor flow creates die-fill weight variation on high-speed rotary presses. A moisture content above 2.5% w/w has been associated with accelerated beta-lactam hydrolysis during closed-container storage, so the sterile grade is typically dried to not more than 2.0% w/w and the oral grade to not more than 3.0% w/w. These are representative release ranges; the exact limit is established from stability data and the intended retest period.

For injectable compounding, the sterile API is reconstituted with water for injection, 0.9% sodium chloride, or 5% glucose. The reconstituted solution is filtered through a 0.22 µm membrane if the downstream process is aseptic fill; if the final product is terminally sterilised by moist heat, the API solution is held in a closed system at a fill temperature that does not exceed 25°C before autoclaving. Filter compatibility should be tested for each formulation; mixed cellulose ester filters may bind cephalosporin APIs, and polyether sulfone or PVDF membranes are commonly preferred for product transfer. The solution should be used within 6 h at 25°C or stored under validated cold-chain conditions because cephalosporin solutions are not stable indefinitely.

The Distinctions Against Ceftriaxone Sodium and Cefotaxime Sodium Are Pharmacokinetic and Handling-Based

Cefodizine sodium differs from ceftriaxone sodium mainly in elimination half-life, protein binding, and calcium-compatibility risk. Published pharmacokinetic studies report an elimination half-life of approximately 3.5–4.5 h for cefodizine after intravenous administration, whereas ceftriaxone has a half-life commonly reported at 6–9 h. This difference means cefodizine is usually administered more than once daily in adult dosing, while ceftriaxone is given once daily. Unlike ceftriaxone, which carries a specific compatibility alert for simultaneous administration with calcium-containing solutions in neonates, cefodizine sodium is not subject to the same neonatal calcium-ceftriaxone precipitation warning; however, compatibility with Ringer’s lactate and other calcium-containing diluents should be confirmed with drug product stability data because cephalosporin salts can form insoluble calcium complexes under certain pH and concentration conditions. Compared with cefotaxime sodium, which undergoes significant metabolism in the liver, cefodizine is predominantly cleared by the kidney, so renal impairment dose adjustments are an operational boundary for injectable use. The beta-lactamase stability spectrum of cefodizine is broadly similar to that of cefotaxime and ceftriaxone: it is not active against methicillin-resistant Staphylococcus aureus or Pseudomonas aeruginosa, and it is not stable against extended-spectrum beta-lactamases. Published data for specific cefodizine-related immunomodulatory activity in human trials are limited; nonclinical reports should not be used as a primary product differentiator.

In raw material purchasing, cefodizine sodium differs from ceftriaxone sodium in the required storage line configuration because cefodizine sodium is more hygroscopic. A production-scale failure mode recorded in batch deviations is moisture ingress through a partially sealed aluminium liner after palletised storage at 25°C/60% RH; this led to a water content rise from 2.1% w/w to 3.8% w/w over six months and a parallel increase in total impurities from 0.8% to 1.6%. This field observation illustrates why storage conditions are specified at 2–8°C and why the primary container closure system must be tested for seal integrity under transport stress. The same degree of moisture sensitivity is not observed to the same extent for some other cephalosporin sodium salts; therefore, cross-use of storage specifications without product-specific stability data is not appropriate.

When Cefodizine Sodium Is Milled, Blended, or Granulated on Production Equipment

Dry milling of cefodizine sodium through a 0.5 mm screen on a hammer mill at ambient relative humidity above 60% has been associated on production campaigns with powder agglomeration, screen blockage, and elevated total impurities. The corrective measure is jacketed milling under nitrogen with a dew point below -40°C, or the use of a cone mill operating at low peripheral speed. In direct compression, blend uniformity is typically achieved using a bin blender at 15–25 rpm for 15–30 min after geometric pre-mixing; over-blending can increase process-related degradants generated by shear and localised temperature rise. Roller compaction for dry granulation is preferred over wet granulation because cefodizine sodium is hydrolytically sensitive in aqueous binder systems. If wet granulation is unavoidable for oral granules, the granulating fluid should be anhydrous or non-aqueous, for example isopropyl alcohol with polyvinylpyrrolidone, and the granule drying temperature should not exceed 40°C at product bed depth above 10 cm. For tablet compression, lubricant content of magnesium stearate should be limited to 0.5–1.0% w/w of total tablet mass because hydrophobic lubrication can delay dissolution; dissolution testing per Ph. Eur. 2.9.3 should confirm equivalent release. These process boundaries derive from standard beta-lactam manufacturing practice and should be verified for each formulation and API lot.

Release Limits, Stability, and Residual Solvent Controls

The batch release profile for sterile cefodizine sodium typically includes identification by infrared spectrophotometry (Ph. Eur. 2.2.24), assay by liquid chromatography at 254 nm (Ph. Eur. 2.2.29), pH of a 10% aqueous solution, specific optical rotation, water content by Karl Fischer titration (Ph. Eur. 2.5.12), residual solvents by headspace gas chromatography, related substances, bacterial endotoxins (Ph. Eur. 2.6.14), and sterility (Ph. Eur. 2.6.1). Residual solvent limits are applied under ICH Q3C: Class 1 solvents are absent or below the detection limit, Class 2 solvents are controlled per the monograph limits, and Class 3 solvents such as ethanol and acetone are typically controlled at not more than 5000 ppm individually or 0.5% w/w total. The API should be stored at 2–8°C in sealed aluminium containers under nitrogen; storage at 25°C/60% RH for prolonged periods may result in colour change, moisture ingress, and increased related substances. Repeated opening of sterile API containers outside an ISO Class 5 zone is not recommended because the sterility claim is lost once the primary container is breached.

Cefodizine sodium should not be mixed with aminoglycoside solutions in the same intravenous container; separate infusion sites are required because of potential physicochemical interaction. Alkaline diluents above pH 8.0 accelerate beta-lactam hydrolysis, and exposure of reconstituted solutions to temperatures above 25°C for more than 6 h without site-specific stability data is outside the recommended injection window. For tablet and capsule formulations, direct contact with high concentrations of magnesium stearate under high shear can reduce dissolution through hydrophobic coating; the lubricant content should therefore be limited to 0.5–1.0% w/w of the total tablet mass unless dissolution testing according to Ph. Eur. 2.9.3 demonstrates equivalent release. Published data for oral solid-dosage performance of cefodizine sodium are limited; the material is primarily described in parenteral use, and oral product development requires new bioavailability and stability studies.